Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
While therapeutic drug monitoring is a potentially attractive strategy that can be utilized by clinical pharmacologists to optimize drug dosing, the costs and risks must be balanced against the potential benefits. However, there is great uncertainty regarding the optimal population dose for most oncology drugs, given the lack of randomized dose-ranging phase II trials. Therefore, efforts to individualize dosing are for the most part premature for such agents.
Cisplatin Ototoxicity Despite the development of novel classes of therapeutics, cytotoxic chemotherapy agents remain crucial components of standard oncology regimens. Numerous pharmacogenomic investigations have been performed to identify predisposing genetic factors to cisplatin toxicities, and one particular toxicity that has garnered significant interest is ototoxicity.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.